Located in Boston’s Seaport District, Ratio’s new facility will advance the company’s targeted radiotherapies for cancer.
Alongside its new premises, Ratio has said it will continue to recruit biologists, chemists and data scientists to join its team of experts.
"We are excited about opening Ratio's state-of-the-art facility that will enable us to accelerate the development of our proprietary platforms to bring novel radiopharmaceuticals to patients in need," said Dr. Jack Hoppin, Ratio chairman and CEO.
"The new headquarters will house biochemistry, medicinal chemistry, radiochemistry and biology labs, as well as office spaces that can accommodate up to 65 total personnel. Ratio has hired 10 new teammates this year and we will continue to grow the team as we expand our efforts."
The news comes after Ratio secured more than $40 million in Series A funding back in February 2023. The company is now poised to enter the clinic "at light speed" with its two proprietary R&D platforms, Trillium and Macropa, and its strategic partnerships with Bayer and Merck.
Ratio is passionate about bringing innovative cancer therapies to patients, with the goal of extending life while maintaining its quality, said Dr. John Babich, president and chief scientific officer at Ratio.
“As we expand the company's assets, we also will look forward to becoming the partner of choice for pharmaceutical companies dedicated to this area of cancer therapies,” he added.
